Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/47352
Title: | The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study | Authors: | Sozeri B. Ulu K. Kaya-Akça U. Haslak F. Pac-Kisaarslan A. Otar-Yener G. Baba O. Altug-Gucenmez, Ozge Sahin, Nihal Bağlan, Esra Sönmez, Hafize Emine Cakmak, Figen Ozturk, Kubra Gezgin-Yıldırım, Deniz Şener, Seher Barut, Kenan Batu, Ezgi Deniz Yıldız, Mehmet Basaran, Ozge Adrovic, Amra Sahin, Sezgin Ozdel, Semanur Bilginer, Yelda Poyrazoglu, Muammer Hakan Demir, Ferhat Yuksel, Selcuk Kalyoncu, Mukaddes Kasapcopur, Ozgur Ozen, Seza Aktay-Ayaz, Nuray |
Keywords: | Biologic drugs COVID-19 Pediatrics Rheumatic disease abatacept adalimumab anakinra azithromycin canakinumab rituximab tocilizumab tofacitinib antirheumatic agent biological product Article artificial ventilation biological therapy child computer assisted tomography connective tissue coronavirus disease 2019 disease activity disease course enzyme linked immunosorbent assay female hospital patient hospitalization human major clinical study male multicenter study pediatric patient polymerase chain reaction prevalence retrospective study rheumatic disease Severe acute respiratory syndrome coronavirus 2 adolescent complication disease exacerbation Adolescent Antirheumatic Agents Biological Products Child COVID-19 Disease Progression Female Humans Male Retrospective Studies Rheumatic Diseases |
Publisher: | Springer Science and Business Media Deutschland GmbH | Abstract: | The effects of biological disease-modifying antirheumatic drugs (bDMARDs) in the clinical course of COVID-19 on children with underlying rheumatologic diseases have not been fully demonstrated. To evaluate the course of COVID-19 infection in patients with rheumatic disease receiving bDMARD treatment. This was a retrospective, multicenter study conducted in pediatric patients infected by SARS-CoV-2 and under bDMARDs therapy. The study population consisted of 113 patients (72 female/41 male). The mean age of the patients was 12.87 ± 4.69 years. The primary diagnosis of the cohort was as follows: 63 juvenile idiopathic arthritis, 35 systemic autoinflammatory diseases, 10 vasculitides, and five cases of connective tissue diseases. The mean duration of the primary disease was 4.62 ± 3.65 years. A total of 19 patients had additional comorbid diseases. Thirty-five patients were treated with canakinumab, 25 with adalimumab, 18 with etanercept, 10 with infliximab, nine with tocilizumab, six with rituximab, four with anakinra, three with tofacitinib, and one with abatacept. The median exposure time of the biological drug was 13.5 months. Seventy-one patients had symptomatic COVID-19, while 42 were asymptomatic. Twenty-four patients required hospitalization. Five patients presented with MIS-C. The hospitalized patients were younger and had a shorter duration of rheumatic disease compared to ambulatory patients, although the difference was not statistically significant. Steroid usage, presence of fever, and dyspnea were more common among the hospitalized patients. A worsening in the course of both COVID-19 and current disease was not noticed under bDMARDs, however, to end with a strong conclusion multicentric international studies are required. © 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | URI: | https://doi.org/10.1007/s00296-021-05008-w https://hdl.handle.net/11499/47352 |
ISSN: | 0172-8172 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu |
Files in This Item:
File | Size | Format | |
---|---|---|---|
The clinical course of SARS-CoV-2.pdf | 592.09 kB | Adobe PDF | View/Open |
CORE Recommender
SCOPUSTM
Citations
16
checked on Aug 17, 2024
Page view(s)
52
checked on Aug 24, 2024
Download(s)
24
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.